🇺🇸 FDA
Pipeline program

eASC

Cx621-0101

Phase 1 gene_therapy completed

Quick answer

eASC for Localized Adverse Reaction to Administration of Drug is a Phase 1 program (gene_therapy) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Localized Adverse Reaction to Administration of Drug
Phase
Phase 1
Modality
gene_therapy
Status
completed

Clinical trials